Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBSA0103 single injection versus Synvisc three injections in knee osteoarthritis
ChiCTR2400090323Phase 3Completed
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2024
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Synovian in knee osteoarthritis (OA) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Change in WOMAC-Likert pain score at 13 weeks after final administration from baseline. Started Sep 2024; status: completed.
02
Drugs
Synovian
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on ChiCTR2400090323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090323.